{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:22:18Z","timestamp":1773408138620,"version":"3.50.1"},"reference-count":15,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T00:00:00Z","timestamp":1493078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Patients with hematologic malignancies are at high risk for both thrombosis and bleeding. During the prolonged periods of thrombocytopenia experienced by patients who are receiving intensive chemotherapy, clinicians often hesitate to prescribe any protection against thrombosis. In case of anticoagulant prescription, it is the prescribers' responsibility to weigh risks and benefits for each patient. Current guidelines exist but do not take into account types of thrombosis, patients' comorbidities, or previous bleeding events.<\/jats:p><\/jats:sec><jats:sec><jats:title>STUDY DESIGN AND METHODS<\/jats:title><jats:p>We proposed to gain insight into hematologists' beliefs about antithrombotic prescription in hematologic malignancy patients, to design future clinical trials. Therefore, we conducted a survey in France to evaluate the practices among a panel of hematologists.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>We found that more than 92% of the respondents prescribed therapeutic anticoagulation in case of pulmonary embolism or deep venous thrombosis. In the case of therapeutic anticoagulation, only 64% of the physicians reconsidered treatment under a platelet threshold of 50 \u00d7\u00a010<jats:sup>9<\/jats:sup>\/L. None of the respondents decided to renounce treatment, nor to discontinue it because of thrombocytopenia, except in distal venous thrombosis or superficial vein thrombosis. One\u2010fifth of clinicians proposed the insertion of a vena cava filter.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>As observed in the United States and Canada, we noticed discrepancies between recommendations and current practices in France. This highlights the urgent need to conduct studies to evaluate both efficacy and safety of antithrombotics in patients with hematologic cancer and thrombocytopenia.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.14120","type":"journal-article","created":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T08:10:01Z","timestamp":1493107801000},"page":"1717-1723","source":"Crossref","is-referenced-by-count":8,"title":["Antithrombotic therapy and platelet transfusions in hematologic malignancy patients presenting chemotherapy\u2010induced thrombocytopenia: a French survey"],"prefix":"10.1111","volume":"57","author":[{"given":"Emilie","family":"Chalayer","sequence":"first","affiliation":[{"name":"Centre d'Investigation Clinique\u2013CIC 1408"},{"name":"Intensive Care Unit CHU Saint Etienne Saint Etienne France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doriane","family":"Cavalieri","sequence":"additional","affiliation":[{"name":"Hematology Unit CHU Clermont\u2010Ferrand Clermont\u2010Ferrand France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Alain","family":"Martignoles","sequence":"additional","affiliation":[{"name":"Hematology Unit Institut de Cancerologie de la Loire Saint Priest en Jarez France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Genthon","sequence":"additional","affiliation":[{"name":"Hematology Unit Institut de Cancerologie de la Loire Saint Priest en Jarez France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Tavernier","sequence":"additional","affiliation":[{"name":"Hematology Unit Institut de Cancerologie de la Loire Saint Priest en Jarez France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Tardy","sequence":"additional","affiliation":[{"name":"Centre d'Investigation Clinique\u2013CIC 1408"},{"name":"Intensive Care Unit CHU Saint Etienne Saint Etienne France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,4,25]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.4.458"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23158"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(10)70024-4"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04215.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-117051"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0108"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216631407"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.06.011"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.1118"},{"key":"e_1_2_8_11_1","first-page":"CD010983","article-title":"Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation","volume":"11","author":"Estcourt LJ","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60689-8"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1212772"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12338"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2016.03.011"},{"key":"e_1_2_8_16_1","unstructured":"Recommandation de bonne pratique. Transfusion de plaquettes: produits indications. [Internet]. Paris: Haute Autorit\u00e9 de sante;2015[cited 2016 Mar 16]. Available from:http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2015-11\/recommandations_-_transfusion_de_plaquettes.pdf."}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftrf.14120","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.14120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T19:08:23Z","timestamp":1696187303000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.14120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,25]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1111\/trf.14120"],"URL":"https:\/\/doi.org\/10.1111\/trf.14120","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,25]]}}}